iDNA Genomics reports wider 2025 loss and increased net liabilities
Cyprus-based iDNA Genomics reported a €3.46 million loss for 2025 as total assets declined and net liabilities increased.
Nicosia, Cyprus. Biotechnology company iDNA Genomics Public Ltd has approved its audited consolidated financial statements for 2025, reporting a wider annual loss and a deterioration in its balance sheet compared with 2024.
The company recorded a loss attributable to shareholders of €3.46 million in 2025, compared with a loss of €2.97 million the previous year.
Annual report and meeting
The board approved the annual report and audited consolidated financial statements for the year ended December 31, 2025, prepared in accordance with applicable legislation and accounting standards.
The report includes the consolidated financial statements, the management report and the independent auditors’ report.
It will be sent to shareholders and published on the company’s website. Printed copies will be available free of charge from the company’s registered office in Nicosia.
The annual general meeting is scheduled for September 25, 2026, at 10.30am and will be held electronically.
Financial position
The company said its financial position, development and performance were not considered satisfactory, with the board working to limit losses.
Total group assets fell to €1.14 million at the end of 2025 from €2.86 million a year earlier.
Net liabilities increased to €4.21 million, compared with €664,091 in 2024.
Operations
iDNA Genomics operates in genomics and biotechnology, specialising in personalised healthcare and providing genetic testing services through medical professionals and directly to consumers.
This news item was generated automatically by Cyprus Inform from publicly available materials. Report an error →
